Brain control of hyperarousal in PTSD
Neural regulation of susceptibility to hyperarousal
This project looks at how a part of the brain that releases norepinephrine causes long-lasting hyperarousal after trauma and whether reducing that brain activity or related inflammation could help people with PTSD who face higher heart risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11212821 on NIH RePORTER |
What this research studies
Researchers use a rat model in which animals witness social defeat to mimic traumatic experiences and produce long-lasting hypervigilance similar to PTSD. They measure activity in the locus coeruleus (the brain's norepinephrine source), levels of inflammatory signals like IL‑1β, and heart and behavioral responses to identify drivers of persistent hyperarousal. The team studies both males and females to understand sex differences in these brain–body responses. They test whether lowering locus coeruleus activity or inflammation reduces the behavioral and cardiovascular signs of hypervigilance.
Who could benefit from this research
Good fit: People with PTSD who experience ongoing hypervigilance, frequent startle responses, or persistently elevated heart rate or blood pressure after trauma would be most relevant to these findings.
Not a fit: Patients whose PTSD symptoms do not include heightened sympathetic activity or whose difficulties stem primarily from other issues (for example, predominant mood symptoms without hyperarousal) may not see direct benefit from these specific findings.
Why it matters
Potential benefit: If successful, this work could point to new treatments that reduce traumatic hyperarousal and lower cardiovascular risk in people with PTSD.
How similar studies have performed: Prior animal studies have linked locus coeruleus norepinephrine to PTSD-like hyperarousal and some drugs that blunt noradrenergic signaling have shown promise, while targeting brain IL‑1β in this context is a relatively new approach.
Where this research is happening
Columbia, United States
- Veterans Health Administration — Columbia, United States (Active)
Researchers
- Principal investigator: Wood, Susan Kathleen — Veterans Health Administration
- Study coordinator: Wood, Susan Kathleen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.